⌕
Incyte · INCY · Nasdaq
Tenet 60 · Solid
Compare
$119.09−0.98%At closeTenet 60 · Solid
$119.09−1.18 (−0.98%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Incyte (INCY) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is INCY's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 17, 2026 · 13:53 ET
Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 Transcript

Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 Transcript…

INCY −1.0% todayRead at source ↗
● Zacks Investment ResearchNov 17, 2026 · 11:16 ETEARNINGS EXPECTED BY FEB 10
INCY Wins European Commission Nod For Skin Disease Drug

Incyte secures EC approval for Povofortay, the first once-daily oral HS treatment in the EU, opening a new growth opportunity backed by strong clinical results.…

INCY −1.0% todayRead at source ↗
● Seeking AlphaNov 17, 2026 · 06:42 ET
Incyte Corporation (INCY) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Incyte Corporation (INCY) Presents at Jefferies Global Healthcare Conference 2026 Transcript…

INCY −1.0% todayRead at source ↗
● ReutersNov 16, 2026 · 16:54 ET
Incyte says EU approves oral treatment for chronic skin disease

Incyte says EU approves oral treatment for chronic skin disease…

INCY −1.0% todayRead at source ↗
● Business WireNov 16, 2026 · 16:30 ET
Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa.…

INCY −1.0% todayRead at source ↗
● Defense WorldNov 15, 2026 · 11:19 ETEARNINGS EXPECTED BY FEB 10
Incyte Corporation $INCY Stock Position Cut by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. decreased its position in Incyte Corporation (NASDAQ: INCY) by 13.0% during a recent quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm own…

INCY −1.0% todayRead at source ↗
● MarketBeatNov 11, 2026 · 08:12 ET
Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030

Incyte NASDAQ: INCY is preparing for a transition away from its JAKAFI business, with Chief Executive Officer Bill Meury pointing to product launches and a pipeline of late-stage drug candidates as potential sources of g…

INCY −1.0% todayRead at source ↗
● Seeking AlphaNov 10, 2026 · 13:00 ET
Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript

Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript…

INCY −1.0% todayRead at source ↗
● Business WireNov 10, 2026 · 07:00 ET
Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) f…

INCY −1.0% todayRead at source ↗
● Business WireNov 6, 2026 · 10:40 ET
2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte is proud to announce that the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute have been selected as the recipients of the 2026 Inc…

INCY −1.0% todayRead at source ↗
● Defense WorldNov 5, 2026 · 04:07 ETEARNINGS EXPECTED BY FEB 10
Incyte Corporation $INCY Shares Newly Purchased by Compass Financial Management LLC

Compass Financial Management LLC bought a new position in shares of Incyte Corporation (NASDAQ: INCY) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Com…

INCY −1.0% todayRead at source ↗
● Defense WorldNov 3, 2026 · 03:05 ETEARNINGS EXPECTED BY FEB 10
Aware Super Pty Ltd as trustee of Aware Super Sells 13,693 Shares of Incyte Corporation $INCY

Aware Super Pty Ltd as trustee of Aware Super lowered its position in Incyte Corporation (NASDAQ: INCY) by 4.5% during a recent quarter, according to the company in its most recent Form 13F filing with the SEC. The firm …

INCY −1.0% todayRead at source ↗
● 24/7 Wall StreetOct 30, 2026 · 08:14 ET
Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.

Pre-Market Stock Futures: Futures are trading lower this Friday, with the Nasdaq down almost 2.…

INCY −1.0% todayRead at source ↗
● BenzingaOct 30, 2026 · 08:10 ET
Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.…

INCY −1.0% todayRead at source ↗
● Seeking AlphaOct 30, 2026 · 02:21 ETEARNINGS EXPECTED BY FEB 10
Incyte: Upgrading To Hold After ESMO Closed The Valuation Gap

I upgraded Incyte to Hold, with a fair value of $112.19 per share, now just 4% below the market price. ESMO Phase 1 data for KRAS G12D and TGFβR2×PD-1 support higher approval probabilities. Q3 net sales rose 14% year-ove…

INCY −1.0% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 16:15 ETEARNINGS EXPECTED BY FEB 10
INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised

Incyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.…

INCY −1.0% todayRead at source ↗
● Seeking AlphaOct 29, 2026 · 15:18 ETEARNINGS EXPECTED BY FEB 10
Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript

Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript…

INCY −1.0% todayRead at source ↗
● MarketBeatOct 29, 2026 · 14:15 ETEARNINGS EXPECTED BY FEB 10
What Incyte (INCY) Said on Its Q3 Earnings Call

Incyte NASDAQ: INCY reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in Jakafi sales. The com…

INCY −1.0% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 10:31 ETEARNINGS EXPECTED BY FEB 10
Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the…

INCY −1.0% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 09:36 ETEARNINGS EXPECTED BY FEB 10
Incyte (INCY) Reports Q3 Loss, Beats Revenue Estimates

Incyte (INCY) came out with a quarterly loss of $3.6 per share versus the Zacks Consensus Estimate of a loss of $3.99. This compares to earnings of $2.26 per share a year ago.…

INCY −1.0% todayRead at source ↗
● Business WireOct 29, 2026 · 07:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 10
Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates.…

INCY −1.0% todayRead at source ↗
● Seeking AlphaOct 27, 2026 · 04:49 ET
Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript

Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript…

INCY −1.0% todayRead at source ↗
● MarketBeatOct 26, 2026 · 22:02 ET
Incyte Highlights Promising Early Data for '890 and '734 in GI Cancers

Incyte NASDAQ: INCY presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “'890,” and INCB161734, a KR…

INCY −1.0% todayRead at source ↗
● Zacks Investment ResearchOct 26, 2026 · 12:26 ET
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy

INCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.…

INCY −1.0% todayRead at source ↗
● Business WireOct 26, 2026 · 09:45 ETCOMPANY'S OWN WORDS
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO26--Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026.…

INCY −1.0% todayRead at source ↗
● Business WireOct 24, 2026 · 07:01 ET
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

COPENHAGEN, Denmark & WILMINGTON, Del.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab's investigational IgG1-bispecif…

INCY −1.0% todayRead at source ↗
● Business WireOct 24, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)---- $INCY--Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer.…

INCY −1.0% todayRead at source ↗
● Business WireOct 18, 2026 · 18:05 ETCOMPANY'S OWN WORDS
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO2026--Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026.…

INCY −1.0% todayRead at source ↗
● Business WireOct 13, 2026 · 13:49 ETCOMPANY'S OWN WORDS
Incyte Honors the 2026 MPN Heroes®, Celebrating Champions of the Myeloproliferative Neoplasm (MPN) Community

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte today announced eight winners of the 2026 MPN Heroes® annual recognition program. The program, now in its 14th year, pays tribute to individuals whose contributions to patient ca…

INCY −1.0% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 10. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA31−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just INCY · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.